

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/821, 930
				Filing Date	April 12, 2004
				First Named Inventor	Dario Neri
				Group Art Unit	1645
				Examiner Name	Virginia Allen Portner
				Attorney Docket Number	ELLIS-0002-P02-C01
Sheet	1	of	9		

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	A1	4 341 223	A	Lutz, Lauralee A	07-27-1982
	A2	5 120 830	A	SANTORO et al.	06-09-1992
	A3	5 534 254		HUSTON et al.	07-09-1996
	A4	5 576 195	A	ROBINSON et al.	11-19-1996
	A5	5 583 203	A	HEMLER et al.	12-10-1996
	A6	RE 35 500		RHODES, Buck A.	05-06-1997
	A7	5 876 691		CHESTER et al.	03-02-1999
	A8	6 083 485		LICHA et al.	07-04-2000
	A9	6 171 578	B1	DEAN et al.	01-09-2001
	A10	6 296 831		WELLER et al.	10-02-2001
	A11	6 342 326		MILTON	01-29-2002
	A12	6 342 219	B1	THORPE et al.	01-29-2002
	A13	6 630 570		LICHA et al.	10-07-2003
	A14	7 129 254		BERGER et al.	10-31-2006
	A15	7 335 775		BERGER et al.	02-26-2008

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	EP	0396612	A1	Int. Genetic Eng.	11-14-1990		
	B2	WO	94 09817	A	City of Hope	05-11-1994		
	B3	WO	95 32001	A1	Molteni & C Dei Fratelli Alitt	11-30-1995		
	B4	EP	0719790	A2	Nihon Mediphysics Co. Ltd.	07-03-1996		
	B5	EP	0760679	A1	Molteni & C Dei Fratelli Alitt	03-12-1997		B3

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 9

### Complete if Known

Application Number	10/821, 930
Filing Date	April 12, 2004
First Named Inventor	Dario Neri
Group Art Unit	1645
Examiner Name	Virginia Allen Portner
Attorney Docket Number	ELLIS-0002-P02-C01

	B6	WO	99 51265	A1	Univ. Oklahoma State	10-14-1999		
	B7	WO	99 58570	A2	Eidgenoess Tech Hoch.	11-18-1999		
	B8	WO	01 23005	A1	Schering AG	04-05-2001		B15
	B9	CA	2385593	A1	Schering AG	04-05-2001		
	B10	EP	1130099	A1	Crucell Holland BV	09-05-2001		
	B11	WO	01 96599	A2	Philogen S.R.L.	12-20-2001		
	B12	WO	03 055917	A2	Schering AG	07-10-2003		
	B13	WO	03 076469	A2	Philogen S.R.L.	09-18-2003		
	B14	WO	01 023005	R	Schering AG	11-13-2000		
	B15	AU	779026	B2	Schering AG	01-06-2005		

Examiner  
Signature

Date  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 9

### Complete if Known

Application Number	10/821, 930
Filing Date	April 12, 2004
First Named Inventor	Dario Neri
Group Art Unit	1645
Examiner Name	Virginia Allen Portner
Attorney Docket Number	ELLIS-0002-P02-C01

### NON PATENT LITERATURE DOCUMENTS


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	ALBERTS et al., "Cells Can Be Redesigned to Produce Proteins of Any Desired Sequence." ( <i>Molecular Biology of the Cell</i> ), 1984, 323-324, 3.	
	C2	ARGRAVES et al., "Amino Acid Sequence of the Human Fibronectin Receptor." ( <i>Journal of Cell Biology</i> ), 1987, 1183-1190, 105.	
	C3	BATISTA et al., "The two membrane isoforms of human IgE assemble into functionally distinct b cell antigen receptors." ( <i>The Journal of Experimental Medicine</i> ), 1996-05-01, 2197-2205, 184:6.	
	C4	BAUTERS et al., "Accumulation of fetal fibronectin mRNAs after balloon denudation of rabbit arteries." ( <i>Circulation</i> ), 1995, 904-911, 92, pp. 904-911, 1995.	
	C5	BERNDORFF et al., "Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments." ( <i>Journal of Nuclear Medicine</i> ), Oct. 2006, 1707-1716, 47:10.	
	C6	BERNDORFF et al., "Radioimmunotherapy of Solid Tumors by Targeting Extra Domain B Fibronectin: Identification of Best-Suited Radioimmunoconjugate." ( <i>Clinical Cancer Research</i> ), 2005, 7053-7063, 11: Suppl. 19.	
	C7	BESTAGNO et al., "Membrane Immunoglobulins Are Stabilized by Interchain Disulfide Bonds Occurring within the Extracellular Membrane-Proximal Domain." ( <i>Biochemistry</i> ), 2001-09-04, 10686-10692, 40:35.	
	C8	BLYTHE et al., "Benchmarking B-cell epitope prediction: Underperformance of existing methods." ( <i>Protein Science</i> ), 2005, 246-248, 14.	
	C9	CALDAS et al., "Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen." ( <i>Molecular Immunology</i> ), May 2003, 941-952, 39:15.	
	C10	CASSET et al., "A peptide mimetic of an anti-CD-4 monoclonal antibody by rational design." ( <i>Biochemical and Biophysical Research Communications</i> ), 2003, 198-205, 307.	
	C11	CASTELLANI et al., "The Fibronectin Isoform Containing the ED-B Oncofetal Domain: A Marker of Angiogenesis." ( <i>International Journal of Cancer</i> ), 1994-12-01, 612-618, 59:5.	
	C12	CHEN et al., "Adhesion Mediated by Fibronectin's Alternatively Spliced Edb (EIIIB) and its neighboring type III repeats." ( <i>Exp. Cell Res.</i> ), 1996-02-25, 9-19, 223:1.	
	C13	CHIEN et al., "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism." ( <i>Proc. Natl. Acad. Sci. USA</i> ), 1989-07, 5532-5536, 86:14.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/821, 930
		Filing Date	April 12, 2004
		First Named Inventor	Dario Neri
		Group Art Unit	1645
		Examiner Name	Virginia Allen Portner
Sheet 4 of 9	Attorney Docket Number	ELLIS-0002-P02-C01	


C14	CHIRIVI et al., "Angiogenesis induced by alternatively spliced oncofetal fibronectin binding to endothelial cell integrin $\alpha 3 \beta 1$ ." ( <i>American Association for Cancer Research</i> ), 2001. Abstract #14.	
C15	COLMAN et al., "Effects of amino acid sequence changes on antibody-antigen interactions." ( <i>Research in Immunology</i> ), 1994, 33-36, 145.	
C16	DINKELBORG et al., "Molecular imaging of atherosclerosis using a technetium-99m-labeled endothelin derivative." ( <i>J. Nuclear Medicine</i> ), 1998, 1819-1822, 39.	
C17	EPSTEIN et al., "FDA Regulation of HIV-Related Tests and Procedures", <i>AIDS Testing: A Comprehensive Guide to Technical, Medical, Social, Legal, and Management Issues</i> , Eds. Schochetman and George, 52-61, Springer-Verlag, New York	
C18	FFRENCH-CONSTANT et al., "Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo." ( <i>Development</i> ) 1989, 375-388, 106.	
C19	FRESHNEY et al., <i>Culture of Animal Cells: A Manual of Basic Technique</i> . Alan R. Liss, Inc., New York, p 4, 1983.	
C20	FOLKMAN et al. "Angiogenesis in cancer, vascular, rheumatoid, and other disease." ( <i>Nature Medicine</i> ), 1995, 27-30, 1.	
C21	GARCIA-VELASCO et al., "Regulation of Monocyte Chemotactic Protein-1 Expression in Human Endometrial Stromal Cells by Integrin-Dependent Cell Adhesion." ( <i>Biology Reproduction</i> ), August 1999, 548-552, 61:2.	
C22	GEORGE et al., "Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: Technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide." ( <i>Proc. Natl. Acad. Sci.</i> ) Aug. 1995, 8358-8362 92:18.	
C23	GIUSTI et al., "Somatic diversification of S107 from an antiphosphocholine to an anti-DNA autoantibody is due to a single base chain in its heavy chain variable region." ( <i>Proc. Natl. Acad. Sci.</i> ), 1987-05, 2926-2930, 84:9.	
C24	GLUKHOVA et al., "Expression of fibronectin variants in vascular and visceral smooth muscle cells in development." ( <i>Developmental Biology</i> ), Sep. 1990, 193-202, 141:1.	
C25	GOEL et al., "99m Tc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid in vivo Localization of Human Colon Carcinoma." ( <i>Journal of Nuclear Medicine</i> ), 2001-10, 1519-1527, 42.	
C26	GREENSPAN et al., "Defining epitopes: It's not as easy as it seems." ( <i>Nature Biotechnology</i> ), 1999, 936-937, 17.	
C27	GUSSOW et al., "Humanization of Monoclonal Antibodies." ( <i>Methods in Enzymology</i> ), 1991, 99-121, 203.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/821, 930
				Filing Date	April 12, 2004
				First Named Inventor	Dario Neri
				Group Art Unit	1645
				Examiner Name	Virginia Allen Portner
Sheet	5	of	9	Attorney Docket Number	ELLIS-0002-P02-C01


C28	HALIN et al., "Antibody-based targeting of Angiogenesis Mediates the Infarction of Solid Tumors in Mice." ( <i>Cancer Research</i> ), 2001-01-15, 711-716, 61.	
C29	HASHIMOTO-UOSHIMA et al., "The Alternatively Spliced Domains EIIB and EIIIA of Human Fibronectin Affect Cell Adhesion and Spreading." ( <i>Journal of Cell Science</i> ), 1997, 2271-2280, 110:18.	
C30	HOLM et al., "Functional mapping and single-chain construction of the anti-cytokeratin 8 monoclonal antibody TS1." ( <i>Mol. Immunol.</i> ), 2007-02, 1075-1084, 44:6.	
C31	ISEMURA et al., "Isolation and Characterization of Human Placenta Fibronectin." ( <i>J. Biochem</i> ), 1984, 163-169, 96.	
C32	KASPAR et al., "Fibronectin as Target for Tumor Therapy." ( <i>Int. J. Cancer</i> ), 2006-05-15, 1331-1339, 118:6.	
C33	KATUGAMPOLA et al., "[ <sup>125</sup> I-His <sup>9</sup> Ghrelin], a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up regulation of receptors with atherosclerosis." ( <i>British Journal of Pharmacology</i> ), 2001, 143-149, 134.	
C34	KERN et al., "Interaction of Type IV Collagen with the Isolated Integrins $\alpha 1 \beta 1$ and $\alpha 2 \beta 1$ ." ( <i>Eur. J. Biochem.</i> ), 1993, 151-159, 215:a.	
C35	KIM et al., "Regulation of angiogenesis in vivo by ligation of integrin $\alpha 5 \beta 1$ with the central cell-binding domain of fibronectin." ( <i>Am. J. Pathol.</i> ), April 2000, 1345-1362, 156:4.	
C36	KOGAN et al., "A Single Amino Acid Residue can Determine the Ligand Specificity of E-Selectin." ( <i>J. Bio. Chem.</i> ), 1995, 14047-14053, 270:23.	
C37	KORVER et al., "Measurement of Primary In Vivo IgM- and IgG-Antibody Response to KLH in Humans: Implications of Pre-Immune IgM Binding in Antigen-Specific ELISA", ( <i>Journal of Immunological Methods</i> ), 1984, 241-251, 74.	
C38	LI et al., "Mammalian cell expression of dimeric small immune proteins (SIP)." ( <i>Protein Engineering</i> ), 1997 731-736, 10:6.	
C39	LIU et al., "Treatment of B-cell Lymphoma with Chimeric IgG and Single-Chain Fv Antibody-Interleukin-2 Fusion Proteins." ( <i>Blood</i> ), 1998-09-15, 2103-2112, 92:6.	
C40	MACCALLUM et al., "Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography." ( <i>J. Mol. Biol.</i> ), 1996-10-11, 732-745, 262:5.	
C41	MAGNUSSON et al., "Fibronectin: structure, assembly, and cardiovascular implications." ( <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> ), Sep. 1998, 1363-1370, 18:9.	
C42	MARIUZZA et al., "The Structural Basis of Antigen-Antibody Recognition." ( <i>Ann. Rev. Biophys. Biophys. Chem</i> ), 1987, 139-159, 16.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/821, 930
		Filing Date	April 12, 2004
		First Named Inventor	Dario Neri
		Group Art Unit	1645
		Examiner Name	Virginia Allen Portner
Sheet 6 of 9	Attorney Docket Number	ELLIS-0002-P02-C01	

C43	MARTY et al., "Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in <i>Pichia pastoris</i> ." ( <i>Protein Expr Purif.</i> ) Feb. 2001, 156-164, 21:1.	
C44	MATSUURA et al., "An $\alpha$ -N-Acetyl Galactosaminylation at the Threonine Residue of a Defined Peptide Sequence Creates the Oncofetal Peptide Epitope in Human Fibronectin." ( <i>The Journal of Biological Chemistry</i> ), 1989, 10472-10476, 264:18.	
C45	MATSUURA et al., "The oncofetal domain of fibronectin defined by monoclonal antibody FDC-6: Its presence in fibronectins from fetal and tumor tissues and its absence in those from normal adult tissues and plasma." ( <i>Proc. Natl. Acad. Sci.</i> ), 6517-6521, 82.	
C46	MENRAD et al., "ED-B fibronectin as a target for antibody-based cancer treatments." ( <i>Expert Opinion Therapeutic Targets</i> ), 2005, 491-500, 9:3.	
C47	MORIKAWA et al., "Radioimmunoassay for TA-0910, a new stable thyrotropin releasing hormone analogue and its metabolite, TA-0910 acid type, in human plasma and urine." ( <i>Journal of Pharmaceutical and Biomedical Analysis</i> ), 1998, 1267-1274, 16.	
C48	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox in the Protein Folding Problem," Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Birkhauser, 1994, 435-508.	
C49	NOZAWA et al., "HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Mullerian Duct-Related Carcinomas." ( <i>Clinical Cancer Research</i> ), 2004-10-15, 7071-7078, 10.	
C50	Office Action of Final Rejection filed on April 21, 2004 issued in USSN 10/321,558	
C51	Office Action of Final Rejection filed on December 5, 2008 issued in USSN 10/321,558	
C52	Office Action of Final Rejection filed on June 21, 2006 issued in USSN 10/336,041	
C53	Office Action of Final Rejection filed on May 15, 2009 issued in USSN 11/637,810	
C54	Office Action of Final Rejection filed on November 13, 2007 issued in USSN 10/321,558	
C55	Office Action of Final Rejection filed on November 14, 2007 issued in USSN 10/336,041	
C56	Office Action of Final Rejection filed on November 27, 2009 issued in USSN 10/336,041	
C57	Office Action of Final Rejection filed on October 18, 2006 issued in USSN 10/088,866	
C58	Office Action of Final Rejection filed on October 31, 2007 issued in USSN 10/966,097	
C59	Office Action of Final Rejection filed on September 1, 2005 issued in USSN 10/088,866	
C60	Office Action of Final Rejection filed on September 12, 2008 issued in USSN 10/088,866	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/821, 930
		Filing Date	April 12, 2004
		First Named Inventor	Dario Neri
		Group Art Unit	1645
		Examiner Name	Virginia Allen Portner
Sheet 7 of 9	Attorney Docket Number	ELLIS-0002-P02-C01	


C61	Office Action of Non-Final Rejection filed on April 9, 2007 issued in USSN 10/966,097	
C62	Office Action of Non-Final Rejection filed on August 6, 2007 issued in USSN 10/088,866	
C63	Office Action of Non-Final Rejection filed on December 12, 2007 issued in USSN 11/105,475	
C64	Office Action of Non-Final Rejection filed on December 17, 2008 issued in USSN 10/966,097	
C65	Office Action of Non-Final Rejection filed on February 1, 2006 issued in USSN 10/088,866	
C66	Office Action of Non-Final Rejection filed on February 18, 2005 issued in USSN 10/088,866	
C67	Office Action of Non-Final Rejection filed on January 8, 2009 issued in USSN 10/321,558	
C68	Office Action of Non-Final Rejection filed on July 14, 2009 issued in USSN 10/321,558	
C69	Office Action of Non-Final Rejection filed on June 22, 2006 issued in USSN 10/088,866	
C70	Office Action of Non-Final Rejection filed on June 25, 2004 issued in USSN 10/321,558	
C71	Office Action of Non-Final Rejection filed on June 29, 2009 issued in USSN 10/088,866	
C72	Office Action of Non-Final Rejection filed on June 3, 2008 issued in USSN 11/105,475	
C73	Office Action of Non-Final Rejection filed on March 18, 2009 issued in USSN 10/336,041	
C74	Office Action of Non-Final Rejection filed on March 5, 2007 issued in USSN 10/336,041	
C75	Office Action of Non-Final Rejection filed on May 30, 2007 issued in USSN 10/321,558	
C76	Office Action of Non-Final Rejection filed on October 1, 2008 issued in USSN 11/637,810	
C77	Office Action of Non-Final Rejection filed on September 22, 2005 issued in USSN 10/336,041	
C78	ORLOVA et al, "Comparative Biodistribution of the radiohalogenated (BR, I and At) antibody A33. Implications for in vivo dosimetry." ( <i>Cancer Biotherapy and Radiopharmaceuticals</i> ), 2002, 385-396, 17:4.	
C79	PASCALIS et al., "Grafting of 'abbreviated' complementarity-determining regions containing specific-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody." ( <i>Journal of Immunology</i> ), 2002, 3076-3084, 169.	
C80	PASQUALINI et al., "α-V integrins as receptors for tumor targeting by circulating ligands." ( <i>Nature Biotechnology</i> ), June 1997, 542-546, 15.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/821, 930
				Filing Date	April 12, 2004
				First Named Inventor	Dario Neri
				Group Art Unit	1645
				Examiner Name	Virginia Allen Portner
Sheet	8	of	9	Attorney Docket Number	ELLIS-0002-P02-C01


C81	POON et al., "Laser-Induced Fluorescence: Experimental Intraoperative Delineation of Tumor Resection Margins." ( <i>J. Neurosurgery</i> ), 1992, 679-686, 76:4.	
C82	RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity." ( <i>Proc. Natl. Acad. Sci. USA</i> ), March 1982, 1979-1983, 79.	
C83	SCHIER et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site." ( <i>J. Molecular Biology</i> ), 1996, 551-567, 263.	
C84	Swiss-Prot accession number A2KBB9 dated 2007-02-20, Anti-ED-B scFV antibody, from PINI et al. "Design and use of a phage display library." ( <i>Journal Biol. Chem.</i> ) see: EMBL; AJ006111; CAA06862.1; -; mRNA.	
C85	Swiss-Prot accession number A2KBC0 dated 2007-02-20, Anti-ED-B scFV antibody, from PINI et al. "Design and use of a phage display library." ( <i>Journal Biol. Chem.</i> ) see: EMBL; AJ006112; CAA06863.1; -; mRNA.	
C86	Swiss-Prot accession number A2KBC2 dated 2007-02-20, Anti-ED-B scFV antibody, from PINI et al. "Design and use of a phage display library." ( <i>Journal Biol. Chem.</i> ) see: EMBL; AJ006114; CAA06865.1; -; mRNA.	
C87	Swiss-Prot accession number A2KBC3 dated 2007-02-20, Anti-ED-B scFV antibody, from PINI et al. "Design and use of a phage display library." ( <i>Journal Biol. Chem.</i> ) see: EMBL; AJ006115; CAA06866.1; -; mRNA.	
C88	Swiss-Prot accession number A2KBC1 dated 2007-02-20, Anti-ED-B scFV antibody, from PINI et al. "Design and use of a phage display library." ( <i>Journal Biol. Chem.</i> ) see: EMBL; AJ006113; CAA06864.2; -; mRNA.	
C89	TAIT et al., "Development and Characterization of Annexin V Mutants with Endogenous Chelation Sites for Tc." ( <i>Bioconjugate Chem.</i> ), 2000, 918-925, 11.	
C90	TAKADA et al., "The Primary Structure of the VLA-2/Collagen Receptor Alpha2 Subunit (Platelet GPIA): Homology to Other Integrins and the Presence of a Possible Collagen-Binding Domain." ( <i>Journal of Cell Biology</i> ), 1989-07-01, 397-407, 109:1.	
C91	U.S. Patent Application No. 10/088,866 filed July 2, 2002.	
C92	U.S. Patent Application No. 10/204,581 filed March 10, 2003 and published on January 22, 2004 under Publication No. US-2004-0013640-A1.	
C93	U.S. Patent Application No. 10/321,558 filed December 18, 2002 and published September 18, 2003 under Publication No. US-2003-0176663-A1.	
C94	U.S. Patent Application No. 10/336,041 filed January 3, 2003 and published on January 1, 2004 under Publication No. US-2004-0001790-A1.	
C95	U.S. Patent Application No. 10/937,882 filed September 10, 2004 and published on April 7, 2005 under Publication No. US-2005-0074401-A1.	
C96	U.S. Patent Application No. 10/966,097 filed October 18, 2004 and published on May 26, 2005 under Publication No. US-2005-0112690-A1.	
Examiner Signature		Date Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/821, 930
				Filing Date	April 12, 2004
				First Named Inventor	Dario Neri
				Group Art Unit	1645
				Examiner Name	Virginia Allen Portner
Sheet	9	of	9	Attorney Docket Number	ELLIS-0002-P02-C01

C97	U.S. Patent Application No. 11/105,475 filed April 14, 2005 and published on October 6, 2005 under Publication No. US-2005-0221434-A1.	
C98	U.S. Patent Application No. 11/249,296 filed October 14, 2005 and published on June 1, 2006 under Publication No. US-2006-0115428-A1.	
C99	U.S. Patent Application No. 11/637,810 filed December 13, 2006 and published August 16, 2007 under Publication No. US-2007-0189963-A1.	
C100	VAJDOS et al., "Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis." ( <i>Journal of Molecular Biology</i> ), 2002, 415-428, 320.	
C101	VANGELISTA et al., "A minimal receptor Ig chimera of human FcεRI α-chain efficiently binds secretory and member IgE." ( <i>Protein Engineering</i> ), 2002-01, 51-57, 15:1.	
C102	WAGNER et al., "Differentiation of Polymorphonuclear Neutrophils in Patients with Systemic Infections and Chronic Inflammatory Diseases: Evidence of Prolonged Life Span and de novo Synthesis of Fibronectin." ( <i>Journal of Molecular Medicine</i> ), 2000, 337-345, 78:6.	
C103	WEIR et al., "An Immunoglobulin G1 Monoclonal Antibody Highly Specific to the Wall of Cryptosporidium Oocysts." ( <i>Clinical and Diagnostic Laboratory Immunology</i> ), Sept. 2000, 745-750, 7:5.	
C104	WILSON et al., "Simvastatin Preserves the Structure of Coronary Adventitial Vasa Vasorum in Experimental Hypercholesterolemia Independent of Lipid Lowering."( <i>Circulation</i> ), 2002-01-29 415-418, 105:4.	
C105	WINKLER et al., "Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody." ( <i>J. Immun.</i> ), 2000, 4505-4514, 265.	
C106	WU et al., "High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment." ( <i>National Academy of Science</i> ), 2000-07-18, 8495-8500, 97:15.	
C107	YANG et al., "CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range." ( <i>Journal of Molecular Biology</i> ), 1995, 392-403, 254.	
C108	ZALUTSKY et al., "Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy." ( <i>Current Pharmaceutical Design</i> ), Sept. 2000, 1433-1455, 6.	
C109	ZHANG et al., "Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation." ( <i>BMC Nuclear Medicine</i> ), 2006, 1-7, 25.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.